Clorox Balances Purell Deal And ERP Overhaul As Margins Squeezed

Simply Wall St

Fri, February 13, 2026 at 5:17 PM GMT+9 4 min read

In this article:

CLX

-1.04%

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

Clorox (NYSE:CLX) completed a US$2.25b acquisition of GOJO Industries, maker of Purell, expanding its health and hygiene portfolio.

The company also finalized a US$580 million ERP system implementation that has been affecting operations and margins.

These two developments come at a time of margin pressure and operational disruption for Clorox.

Clorox, best known for its cleaning and household products, is pushing further into health and hygiene with the GOJO deal. Purell adds a well known hand hygiene brand to a portfolio that already spans cleaning, disinfecting and household staples. For you as an investor, this means more exposure to professional and institutional hygiene markets in addition to consumer shelves.

The new ERP system and the GOJO integration could influence how efficiently NYSE:CLX runs its supply chain, pricing and product mix over time. Both moves increase complexity, so execution risk is an important angle to watch, especially given existing margin pressures. As more details emerge, the key questions center on integration progress, cost discipline and how quickly Clorox can stabilize operations.

Stay updated on the most important news stories for Clorox by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Clorox.

NYSE:CLX Earnings & Revenue Growth as at Feb 2026

📰 Beyond the headline: 1 risk and 4 things going right for Clorox that every investor should see.

For you as a shareholder, the GOJO acquisition and the completed ERP rollout pull Clorox in two directions at once. On one side, Purell gives Clorox a much bigger footprint in professional and institutional hygiene, a category where it can sit alongside players like Procter & Gamble and Reckitt in front of hospitals, offices and schools, not just households. On the other, the US$580 million ERP project and recent operational disruption have coincided with softer results, with quarterly sales at US$1,673 million versus US$1,686 million a year earlier and net income at US$157 million versus US$193 million.

How This Fits Into The Clorox Narrative

The GOJO deal and ERP completion line up with the narrative around digital transformation and building a stronger health and hygiene portfolio that could support future margin and earnings quality once operations are running smoothly.

Recent flat to lower sales and pressured profitability, while Clorox is spending heavily on systems and acquisitions, speak directly to concerns in the narrative about sluggish category growth and execution issues weighing on returns.

The scale and timing of the US$2.25b GOJO purchase, alongside the final ERP spend, add balance sheet and integration considerations that are not fully reflected in the earlier focus on ERP benefits and product launches.

 






Story Continues  

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Clorox to help decide what it’s worth to you.

The Risks and Rewards Investors Should Consider

⚠️ Integration and system risk, bringing GOJO into the fold just as a large ERP rollout has been disrupting margins and operations.

⚠️ Profitability pressure, with net income at US$157 million versus US$193 million a year earlier while Clorox also competes with large peers like Procter & Gamble and Reckitt on pricing and promotions.

🎁 Broader health and hygiene reach, as Purell adds a recognisable brand and commercial relationships that could deepen Clorox’s presence beyond consumer channels.

🎁 Completed ERP program, which, once fully bedded in, could help with cost control, inventory management and product mix decisions across the enlarged business.

What To Watch Going Forward

From here, you may want to follow how quickly Clorox restores margin performance now that the ERP system is live, and whether management can show clean execution in integrating GOJO without fresh disruption. The trajectory of sales and net income after the recent quarter, when both were slightly below the prior year, will be one reference point. It is also worth tracking how Purell and other hygiene products perform versus rivals in key categories, as that will give you a clearer sense of whether the US$2.25b price tag is translating into a stronger competitive position.

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Clorox, head to the community page for Clorox to never miss an update on the top community narratives.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include CLX.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info